1. Clinical & Scientific Overview
Alendronate Sodium & Risedronate (Weekly Oral Bisphosphonates) (TIP-MED-000250, Reference Code [12.18]) is classified under
Osteoporosis & Bone Metabolism Medicines (Ch 12) as a Nitrogen-Containing Oral Bisphosphonate (Osteoclast Farnesyl Pyrophosphate Synthase Inhibitor).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.18], p. 163): Osteofos, Stoplos, Restofos — Strengths & Dosage Forms: Tablet: 10 mg (daily), 35 mg (weekly), 70 mg (weekly; alone or with Cholecalciferol 2800 IU / 5600 IU).
Tablet: 10 mg (daily), 35 mg (weekly), 70 mg (weekly; alone or with Cholecalciferol 2800 IU / 5600 IU).
3. Mechanism of Action & Pharmacodynamics
Binds hydroxyapatite crystals in bone and is internalised by resorbing osteoclasts -> inhibits mevalonate pathway enzyme farnesyl pyrophosphate synthase -> induces osteoclast apoptosis and suppresses bone turnover.
4. Therapeutic Indications & Evidence-Supported Uses
- Postmenopausal osteoporosis
- male osteoporosis
- glucocorticoid-induced osteoporosis
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Adult: Treatment of Osteoporosis: 70 mg PO ONCE WEEKLY on the same day each week (or 10 mg once daily). Prevention: 35 mg PO once weekly. • Paediatric: Specialist osteogenesis imperfecta protocols only.
Administration & Meal Timing: See Administration & Counselling below. | Standard clinical schedule per indication.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: eGFR <35 mL/min: CONTRAINDICATED (renal elimination; risk of adynamic bone disease and nephrotoxicity). • Hepatic: No adjustment required (not metabolised by liver).
Renal: eGFR <35 mL/min: CONTRAINDICATED (renal elimination; risk of adynamic bone disease and nephrotoxicity). • Hepatic: No adjustment required (not metabolised by liver).
Renal: eGFR <35 mL/min: CONTRAINDICATED (renal elimination; risk of adynamic bone disease and nephrotoxicity). • Hepatic: No adjustment required (not metabolised by liver).
7. Contraindications, Precautions & High-Risk Warnings
- Contraindications: Oesophageal stricture, achalasia, or delayed oesophageal emptying; inability to stand or sit upright for at least 30 minutes; hypocalcaemia (must correct vitamin D and calcium deficiency first); eGFR <35 mL/min. • Precautions: Extremely poor oral bioavailability (<1%) that is completely abolished (reduced by 60-90%) by food, coffee, tea, juice, mineral water, calcium, iron, or levothyroxine; causes corrosive pill oesophagitis if lodged in oesophagus; rare osteonecrosis of the jaw (ONJ) after invasive dental extractions and atypical subtrochanteric femoral fractures after >5 years.
Key Clinical Precautions: Renal: eGFR <35 mL/min: CONTRAINDICATED (renal elimination; risk of adynamic bone disease and nephrotoxicity). • Hepatic: No adjustment required (not metabolised by liver).
8. Adverse Effects Profile
- Dyspepsia, abdominal pain, musculoskeletal pain, acid regurgitation.
- Erosive oesophagitis, oesophageal ulceration/stricture, osteonecrosis of the jaw (ONJ), atypical femur fracture, hypocalcaemia.
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Calcium, Iron, Magnesium, Antacids, Sucralfate, Levothyroxine, Milk/Tea/Coffee -> chelate alendronate and abolish absorption (wait >=30-60 minutes before taking ANY food, beverage, or other morning medication including Levothyroxine if taken on the same day); NSAIDs/Aspirin -> additive upper GI ulceration
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: MANDATORY 4-RULE ADMINISTRATION: (1) Take ONCE A WEEK first thing in the morning on an empty stomach, (2) Swallow whole with a full glass (200 mL) of plain tap water ONLY (not mineral water, tea, coffee, or milk), (3) Remain fully upright (sitting or standing—do NOT lie down) for at least 30 minutes, (4) Wait at least 30 minutes before eating breakfast or taking Calcium/Iron/Thyroxine tablets.
- Meal & Clock Timing Instruction: See Administration & Counselling below. (Standard clinical schedule per indication.)
- Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
- Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Yes | Compendia: IP 2026 / NFI 7th Ed 2026 / NLEM 2022 / CDSCO Schedule H / BNF 90th Ed
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Tablet: 10 mg (daily), 35 mg (weekly), 70 mg (weekly; alone or with Cholecalciferol 2800 IU / 5600 IU).
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 12 [12.18] (p. 163)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [12.7]-C156 Denosumab (60 mg SC q6m) — Antiresorptive Nitrogen-Containing Bisphosphonates (Alendronate,
- [12.18]-C166 Risedronate Sodium — Nitrogen-Containing Oral Bisphosphonate (Osteoclast Farnesyl Pyro
- [12.7] Zoledronic Acid (IV Annual Bisphosphonate) & Denosumab (SC RANKL Inhibitor) — Antiresorptive Nitrogen-Containing Bisphosphonates (Alendronate,
- [12.19] Teriparatide (Recombinant PTH 1-34 Osteoanabolic Injection) — Recombinant Human Parathyroid Hormone Fragment [rhPTH(1-34)] (Ost